readthroughSign in
CompanyIFRXNasdaqJena, 2M

InflaRx N.V.

InflaRx develops anti-inflammatory therapeutics targeting complement factor C5a and its receptor.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 6Latest story